Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET Study)

CompletedPhase 4Early (CIS/RIS)2005-001281-13

What it found

No results found

We found no results in the registry or in papers.

What was tested

Treatment tested

What it measured

Main measures

  • Clinical endpoints include:

Who could take part

Early (CIS/RIS)

Show the full criteria

Inclusion criteria

Inclusion: · Clinically isolated syndrome suspected from demyelinating event (no better explanation for present symptoms) Exclusion: · The clinical diagnosis of Multiple Sclerosis is definite (the second attack occurs before the baseline visit)

Exclusion criteria

Not separately supplied in the registry.

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

To determine which high-risk patient groups presenting with a clinically isolated syndrome (CIS) suggestive of multiple sclerosis may have the best clinical outcome from treatment with interferon beta 1-a (Avonex). This study will evaluate the conversion pattern to clinically definite multiple sclerosis in high risk CIS patients treated with (IFN beta-1a IM) (Avonex) during a follow up period of 4 years and will determine risk factors for conversion to CDMS under treatment. Each clinical and MRI end point will be evaluated with its relation to the baseline clinical and MRI characteristics.

Papers

    Loading reviews and guidelines…

    Related trials

    History

      1. Started

        Jul 2005

      Assembled by software from public sources.